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Abstract
Multiple myeloma (MM) patients experience severe bone pain (MMBP) that is undertreated and 
poorly understood. In this study, we studied MMBP in an intratibial mouse xenograft model which 
employs JJN3 human MM cells. In this model, mice develop MMBP associated in bone with 
increased sprouting of calcitonin gene-related peptide-positive (CGRP+) sensory nerves and in 
dorsal root ganglia (DRG) with upregulation of phosphorylated ERK1/2 (pERK1/2) and pCREB, 
two molecular indicators of neuron excitation. We found that JJN3 cells expressed a vacuolar 
proton pump (V-ATPase) that induced an acidic bone microenvironment. Inhibition of JJN3-
colonized bone acidification by a single injection of the selective V-ATPase inhibitor, bafilomycin 
A1, decreased MMBP, CGRP+ SN sprouting, and pERK1/2 and pCREB expression in DRG. 
CGRP+ sensory nerves also expressed increased levels of the acid-sensing nociceptor ASIC3. 
Notably, a single injection of the selective ASIC3 antagonist APETx2 dramatically reduced 
MMBP in the model. Mechanistic investigations in primary DRG neurons co-cultured with JJN3 
cells showed increased neurite outgrowth and excitation inhibited by bafilomycin A1 or APETx2. 
Further, combining APETx2 with bafilomycin A1 reduced MMBP to a greater extent than either 
agent alone. Lastly, combining bafilomycin A1 with the osteoclast inhibitor zoledronic acid was 
sufficient to ameliorate MMBP which was refractory to zoledronic acid. Overall, our results show 
that osteoclasts and MM cooperate to induce an acidic bone microenvironment that evokes MMBP 
as a result of the excitation of ASIC3-activated sensory neurons. Further, they present a 
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mechanistic rationale for targeting ASIC3 on neurons along with the MM-induced acidic bone 
microenvironment as a strategy to relieve MMBP in patients.
Keywords
Osteoclastic bone destruction; bisphosphonates; acidic microenvironment; sensory neurons; 
nociceptors
Introduction
Multiple myeloma (MM) is a malignant plasma cell disorder accounting for approximately 
10% of all hematologic cancers (1). Seventy percent of MM patients present with severe 
bone pain associated with osteolytic bone lesions that result from increased osteoclastic 
bone resorption and reduced osteoblastic bone formation (2). Bone pain contributes to 
increased mortality and morbidity (3). The degree of bone pain in MM is often greater than 
pain experienced with solid tumors (4–6) and bone pain is the most common presenting 
complaint of MM patients (7). Control of bone pain is thus a major goal in the management 
of MM patients. Despite this, the pathophysiology of bone pain associated with MM 
(MMBP) is poorly understood, and MMBP is frequently inadequately treated (3).
Bone is densely innervated by sensory neurons (SNs), especially the calcitonin gene-related 
peptide-positive (CGRP+) SN (8–12), which show pathological sprouting in the presence of 
tumors (13,14). Osteoclasts (OCLs) are also increased in cancer-colonized bone and actively 
secrete protons (H+) to destroy mineralized bone via the plasma membrane a3 isoform 
vacuolar-H+-ATPase (a3V-ATPase) localized in the ruffled borders (15), creating an acidic 
microenvironment (pH range = 4.0–6.0) (16,17). H+ are a well-known potent pain-inducing 
mediator (18,19), suggesting that the acidic microenvironment created by increased H+ 
release from bone-resorbing OCLs via the a3V-ATPase activates pH-sensitive SNs to elicit 
bone pain. Consistent with this notion, specific inhibitors of osteoclastic bone resorption, 
including bisphosphonates (BPs) and denosumab (Dmab), significantly reduce bone pain in 
patients with MM (2,20) and bone metastases of solid cancers (21–23), indicating that OCL 
bone resorption contributes to activation of nociceptive SNs in bone to induce bone pain.
However, BP or Dmab treatment does not prevent the progression of bone pain in bone 
metastasis at advanced stages in patients with solid tumors (22,23), suggesting that tumor 
cells also contribute to bone pain. Solid tumor cells release increased levels of H+ via 
various types of plasma membrane pH regulators, thereby inducing an acidic extracellular 
microenvironment (pH range = 6.5–7.0) (24,25) that can also excite pH-sensitive nociceptive 
SNs innervating bone to evoke bone pain. Similarly, it has been clinically well-recognized 
that MMBP in patients at advanced stages is unresponsive to BPs or Dmab. Thus, MM cells 
may also contribute to induce MMBP through creation of acidic extracellular 
microenvironment via plasma membrane pH regulators as do solid tumors.
A subpopulation of peripheral nerve fibers, termed nociceptors (18), recognize and 
transduce local nociceptive stimuli into electrochemical signals. The nociceptors in turn 
transmit these noxious signals to the central nervous system (CNS) and brain via the dorsal 
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root ganglion (DRG), which is the cell body of primary afferent SN fibers innervating 
peripheral tissues and serves as the gateway for peripheral noxious signals to the CNS (26). 
The specific acid-sensing nociceptors related to acid-induced bone pain are the transient 
receptor potential channel-vanilloid subfamily member 1 (TRPV1) and the acid-sensing ion 
channel 3 (ASIC3) (18). TRPV1 is activated by pH values < 6.0 (27), equivalent to the pH 
under the OCL ruffled border (15–17). Previous studies reported that TRPV1 plays a critical 
role in cancer-associated bone pain (28,29). In contrast, little is known about contributions 
of ASIC3 to bone pain, despite that ASIC3 senses milder pH between 6.5 and 7.0 (30), 
equivalent to the pH of the bone microenvironment of cancer-involved bone (24,25).
In this study, we show that H+ released via V-ATPase by bone-resorbing OCLs and JJN3 
MM cells create an acidic bone microenvironment that excites SNs innervating bone via 
activation of ASIC3 to induce MMBP. Further, blocking the generation of the acidic bone 
microenvironment and the activation of ASIC3 on SNs significantly reduced MMBP and 
could be a mechanism-based therapeutic approach for MMBP.
Materials and Methods
Reagents
The sources for the reagents were as follows. APETx2 and SB366791 (Tocris); zoledronic 
acid monohydrate (Sigma); rabbit monoclonal antibodies to, ERK1/2, CREB, pERK1/2, 
pCREB, HRP-conjugated horse anti-mouse IgG and goat anti-rabbit IgG antibody (Cell 
Signaling); bafilomycin A1, rabbit polyclonal antibodies to ASIC3, TRPV1, the goat 
polyclonal antibody against CGRP, and HRP-conjugated mouse monoclonal antibody 
against β-actin (Abcam); Alexa fluor 488-conjugated donkey anti-rabbit IgG and donkey 
anti-chicken IgY, and rhodamine red-X (RRX)-conjugated donkey anti-goat IgG antibody 
(Jackson); rhodamine phalloidin (Life Technologies); and rabbit polyclonal antibodies to 
RANKL, IL-6, mouse monoclonal antibody to MIP-1α, and HRP-conjugated goat anti-
chicken antibody (Santa Cruz).
Cell culture
The JJN3 human MM cell line was provided by Dr. Giuliani (31). JJN3, H929 and U266 
MM cell lines and primary CD138+ MM cells and CD138− cells (isolated from bone 
marrow aspirates of MM patients using MACS MicroBead) were cultured in RPMI1640 
medium with 5% FBS, 100 units/ml penicillin and 100 mg/ml streptomycin. The mouse 
osteocytic MLO-A5 and MLO-Y4 (Dr. Bellido), mouse osteoblastic MC3T3-E1, and F11 
SN, human breast cancer (BC) MCF-7 and MDA-MB-231 cells were cultured in α-MEM 
(Gibco) with 10% FBS, 100units/ml penicillin and 100mg/ml streptomycin. Primary rat 
DRG SN (1° N) cells (Lonza) were cultured in Primary Neuron Growth Medium (Lonza) 
with 2% FBS. All cell lines were analyzed and authenticated by targeted genomic and RNA 
sequencing. All procedures involving patients were performed with written informed 
consent according to the Declaration of Helsinki and under a protocol approved by the 
Indiana University (IU) Institutional Review Board.
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Animal model of MM
All animal studies were approved by the IACUC at IU School of Medicine. JJN3 cells (5 × 
105) or PBS (sham) were injected into the right tibia marrow of female C57BL/6 SCID mice 
(4–6 week-old) under anesthesia (32).
Behavioral pain tests
Mechanical allodynia and thermal hyperalgesia were evaluated by von Frey and plantar tests 
using the Dynamic Plantar Aesthesiometer and Plantar Test Instrument (Ugo Basile), 
respectively (33,34). These tests are widely used for bone pain assessment in rodents (35). 
Tests were performed prior to MM cell injection to determine baseline behaviors and every 5 
days following cell injection. Throughout the experiment, behavioral tests were performed 
under blind conditions by a single researcher. JJN3 cell injections were performed by a 
researcher blinded to the experiment. The investigator performing the behavioral tests was 
blinded as to the experimental condition of the animals.
Acridine orange accumulation
Acridine orange (Molecular Probes), which selectively deposits and fluoresces in acidic 
environments (36), was injected (1.0 mg/kg) into mice via the tail vein 2h prior to sacrifice. 
Tibiae were excised and acridine orange fluorescence detected using an EVOS fluorescence 
microscope (Advanced Microscopy).
Tartrate-resistant acid phosphatase (TRAP) staining
Bone sections were stained for TRAP activity using a TRACP & ALP double-stain Kit 
(Takara Bio) (32) and analyzed using Magnafire 4.1 software (Optronics) with the IX70 
microscope (Olympus).
C-terminal telopeptides of type I collagen (CTx) measurement
Sera were collected from mice at indicated time, and CTx was measured by RatLaps™ 
(CTX-I) EIA kit (Immunodiagnosticsystems) according to manufacturer’s instruction.
Extracellular pH (pHe) measurement
Cells (105/96-well) were cultured for 48h in the presence of adriamycin (30nM) to prevent 
cell proliferation and pHe was measured by FiveEasy pH meter (Metter Toled) immediately 
after removal from the CO2 incubator.
Knockdown of a3V-ATPase in JJN3 cells
JJN3 cells were infected with 20µL of control (sc-108080) or TCIRG1 (sc-96928-V) shRNA 
lentiviral particles (Santa Cruz) in the presence of 5 µg/ml polybrene. One day later, cells 
were cultured in RPMI1640 plus 5% FBS for 7 days in the presence of 2 µg/ml puromycin 
(Gibco) to select cells stably expressing the shRNAs.
Neurite outgrowth determination
1° N cells (1 × 103/6-well) were co-cultured with JJN3 cells (5 × 103) or alone for 120h. 
Neurite outgrowth was visualized by staining the cultures with calcein AM (Life 
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technologies) and the length of neurites was quantified with a fluorescent microscope using 
Neuron J (37).
Imaging of intracellular Ca2+ influx
1° N or F11 SN cells were seeded in FluoroDish (World Precision) and loaded with fura-2 
AM (3µM, Molecular Probes) for 25 min (38). Intracellular calcium was measured by digital 
video microfluorometry, using an intensified CCD camera coupled to a microscope and 
MetaFluor software (Molecular Devices). Cells were illuminated, and the excitation 
wavelengths for fura-2 (340/380 nm) were selected by a filter changer. Inhibitors were added 
directly into the bathing solution 2h before stimulation with 0.1N hydrochloric acid (HCl).
Immunoblotting
Cells or tissues were lysed in lysis buffer (Invitrogen), electrophoresed on a 10% SDS-
PAGE, and blotted onto PVDF membranes (Biorad) (32). After blocking, the membranes 
were incubated with primary antibodies overnight at 4 °C, and then with HRP-conjugated 
secondary antibodies for 1h. Protein bands were visualized with a SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Fisher).
Immunohistochemistry (IHC)
Bones were fixed, embedded in OCT compound and sectioned at 30µm thickness using a 
cryostat. After blocking, sections were incubated with the primary antibodies overnight at 
4°C, and secondary antibodies for 60 min, mounted with coverslips in VECTASHIELD anti-
fade mounting medium (Vector) and observed under the Leica TCS SP8 confocal laser 
scanning microscope.
For TRAP and CGRP double-staining, sections were first stained with TRAP and incubated 
with anti-CGRP antibody (1/200) overnight at 4°C, and then with HRP-conjugated 
secondary antibodies and diaminobenzidine substrate (Vector).
Immunocytochemistry (ICC)
JJN3 cells (1×103/96-well) were fixed with 10% neutral-buffered formalin, incubated with 
3% BSA-PBS blocking solution, and then with a3V-ATPase antibody (1/200) (39) at 4°C 
overnight, followed by Alexa Fluor® 594 anti-chicken secondary antibody (1/1,000) and 
Alexa Fluor® 488 Phalloidin (1/2,000) were then added. Nuclei were counter-stained with 
DAPI.
Statistical analysis
Data are presented as the mean ± SEM. Statistical differences were determined by 
parametric or nonparametric tests as indicated.
Results
Animal model of MMBP
Mice intratibially injected with JJN3 cells developed characteristic osteolytic lesions on X-
ray (Figure 1A) and µCT (Figure 1B). These lesions showed aggressive proliferation of JJN3 
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cells in bone marrow (Figure 1C) with increased TRAP+ OCL bone resorption (Figure 1D, 
1E) and elevated serum CTx (Figure 1F). We found that JJN3 cells produced 
osteoclastogenic cytokines including RANKL, IL-6 and MIP-1α (Figure 1G). Interestingly, 
MDA-MB-231 human breast cancer cells (25), used as a representative aggressive solid 
cancer cells that develop osteolytic bone lesions to compare with MM cells, showed 
undetectable production of MIP-1α. PBS-injected sham mice exhibited no osteolytic 
lesions.
The right leg of mice harboring JJN3 cells initially displayed mechanical allodynia (Figure 
2A) and thermal hyperalgesia (Figure 2B) at day 20 of post injection and these pain 
behaviors progressed in parallel with bone destruction. Sham mice showed no evidence of 
MMBP (Figure 2A, 2B). Left legs of JJN3-injected mice had no evidence of MMBP, 
demonstrating that MMBP is associated with local JJN3 colonization rather than a systemic 
effect of JJN3 cells. Sprouting of CGRP+ SNs in JJN3-injected bone was increased in 
parallel with the progression of MMBP (Figure 2C, 2D).
5TGM1 MM cells intratibilally injected into immunocompetent C57BL/KaLwRij mice also 
developed osteolytic lesions and induced progressive MMBP (Supplemental Figure 1A and 
1B).
Acidification and MMBP are associated with JJN3-colonized bone
We next determined if the JJN3-colonized bone is acidic using the pH sensor fluorescent 
dye, acridine orange. No fluorescence was detected in the right tibiae of sham mice (Figure 
2E, left). In contrast, the entire marrow of right tibiae injected with JJN3 cells was 
fluorescent (Figure 2E, center), demonstrating that JJN3-colonized bone is acidic. The bone 
marrow injected with 5TGM1 cells was also acidic (Supplemental Figure 1D, right). We 
then assessed if the selective V-ATPase inhibitor, bafilomycin A1 (Baf A1), blocked 
established MMBP in JJN3-injected mice. Baf A1 inhibited acidification by OCL bone 
resorption (40), and, we reported, reduced bone pain in BC bone metastases (41). Repeated 
injections of Baf A1 inhibited tumor growth (42) and bone resorption (40) that alter the 
status of bone pain. To examine if Baf A1 directly inhibits SN activation and reduces MMBP 
independent of inhibition of tumor growth and bone resorption, JJN3-injected mice 
manifesting MMBP and sham mice were given a single intraperitoneal injection of Baf A1 
at day 25 (arrow in Figure 2A and 2B) and evaluated for changes in MMBP as a function of 
time. Baf A1 treatment blocked acidification in JJN3-colonized bone (Figure 2E, right). 
Importantly, Baf A1 blockade of the acidification of JJN3-colonized bone inhibited the 
progression of mechanical allodynia (Figure 2F) and thermal hyperalgesia (Figure 2G) as 
early as 12h after injection. The effects lasted up to 24h and were lost by 48h after injection.
In parallel with noxious behaviors, JJN3-injected mice demonstrated increased expression of 
pERK1/2 and pCREB, which are molecular indicators for neuronal excitation (43), in their 
DRG SNs compared with sham mice (Figure 2H). Similarly, 5TGM1-injected mice also 
exhibited elevated expression of pERK and pCREB in their DRG SNs (Supplemental Figure 
1C). Importantly, the elevated levels of pERK1/2 and pCREB in DRG SNs in JJN3-injected 
mice were decreased at 12h after Baf A1 injection (Figure 2H), indicating that SN 
excitation, as well as noxious behaviors, is inhibited by blocking the acidification of JJN3-
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colonized bone. These results suggest that H+ released via V-ATPase directly excite SNs in 
bone to evoke MMBP. They also suggest that Baf A1 ameliorates MMBP by inhibiting SN 
excitation in a time period too short to be due to inhibition of JJN3 tumor growth and bone 
resorption.
Expression of V-ATPase and pHe in JJN3 cells
We next examined if JJN3 cells contribute to acidification of the bone microenvironment by 
releasing H+ via V-ATPase. Human MM cell lines, JJN3, H929 and U266, and MDA-
MB-231 human BC cell line (serve as a positive control) expressed a3V-ATPase (Figure 
3A). Importantly, CD138+, but not CD138−, cells derived from three MM patients expressed 
a3V-ATPase (Figure 3B). JJN3 expressed the a3V-ATPase on their plasma membrane 
(Figure 3C), as did highly-invasive MDA-MB-231 cells (44). The pHe of JJN3, H929 and 
U266 and MDA-MB-231 and CD138+ cells was acidic (Figure 3D). The human MM cells 
MM.1S expressed undetectable a3V-ATPase (Figure 3A) and the pHe of MM.1S was not 
acidic (Figure 3D). The expression of a3V-ATPase in MC3T3-E1 osteoblastic and MLO-A5 
and MLO-Y4 osteocytic cells was undetectable (Figure 3A) and their pHe was not acidic 
(Figure 3D). Thus, osteoblasts and osteocytes unlikely contribute to extracellular 
acidification of MM-colonized bone. Baf A1 significantly blocked extracellular acidification 
in JJN3 cultures (Figure 3E) with no inhibition of cell proliferation (Figure 3F). In contrast, 
Baf A1 showed no effects on pHe in other cells. Further, knockdown of a3V-ATPase in JJN3 
cells significantly blocked extracellular acidification (Figure 3G).
Thus, the a3V-ATPase contributes to the acidification of JJN3 cell extracellular 
microenvironment. 5TGM1 cells also expressed plasma membrane a3V-ATPase and the pHe 
of 5TGM1 cells was acidic, which was neutralized by Baf A1 (Supplementary Figure 
1E-1G).
Effects of acidic microenvironment of JJN3-colonized bone on SNs
Tumors in bone induce SN sprouting in bone, thereby enhancing bone pain (13,14). We 
therefore determined the extent of CGRP+ SN sprouting with or without treatment with Baf 
A1 in JJN3-colonized bone. Baf A1 inhibited the progression of mechanical allodynia in 
mice injected intratibially with JJN3 cells (Figure 4A). IHC showed increased CGRP+ SN 
sprouting within the CD138+ JJN3 tumor in tibiae (Figure 4B, middle and 4C) compared to 
tibiae of sham mice (Figure 4B, top and 4C). Treatment with Baf A1 decreased the sprouting 
of CGRP+ SNs within the JJN3 tumor in bone (Figure 4B, bottom and 4C).
Thus, the acidic microenvironment of JJN3-colonized bone resulting from H+ release via V-
ATPase increases sprouting of CGRP+ SNs in vivo.
To further analyze the effects of the acidic microenvironment created by JJN3 cells on SN 
sprouting, 1° N cells were co-cultured with JJN3 cells and assessed for neurite outgrowth, an 
in vitro indicator for sprouting (45). Neurite outgrowth of 1°N cells was increased in the co-
cultures (Figure 4D and 4E). Importantly, Baf A1 significantly decreased neurite outgrowth 
of primary DRG neuron cells in the co-cultures (Figure 4D and 4E). Further, neurite 
outgrowth of 1°N cells cultured in media at pH 6.5, which is equivalent to the pHe of JJN3 
cultures, was also increased compared to that cultured in media at pH 7.4 (Figure 4F).
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Thus, H+ released via V-ATPase from JJN3 cells increase neurite outgrowth of SNs in vitro.
Activation of acid-sensing nociceptors by the acidic microenvironment of JJN3-colonized 
bone
To study the mechanism underlying increased sprouting of CGRP+ SNs in bone occurring in 
the acidic microenvironment of JJN3 cells, we determined the expression of the acid-sensing 
nociceptors, ASIC3, on CGRP+ SNs in DRG of JJN3-injected mice. We found increased 
expression of ASIC3 on CGRP+ SNs of DRG in JJN3-injected mice by double 
immunofluorescent (Figure 5A) and Western analysis (Figure 5B) compared to sham mice. 
Expression of the acid-sensing nociceptor, TRPV1, was also increased on CGRP+ SNs of 
DRG in JJN3-injected mice compared to sham mice (Supplemental Figure 2A and 2B). 
Increased neurite outgrowth of 1°N cells in co-cultures with JJN3 cells was reduced by 
treatment with the specific ASIC3 antagonist, APETx2 (46) or Baf A1 (Figure 5C).
We then examined the role of ASIC3 in SN excitation in response to JJN3-induced acidic 
microenvironment by assessing intracellular Ca2+ influx, an early indicator of SN excitation 
in vitro (38), in 1°N cells. Co-culture of 1°N cells with JJN3 cells rapidly induced a transient 
Ca2+ influx (Figure 5D, iii), which was blocked by APETx2 (Figure 5D, iv). Addition of 
culture medium caused no Ca2+ influx (Figure 5D, i). Addition of HCl at a final pH 6.5 also 
induced a Ca2+ influx (Figure 5E), while PBS at pH7.4 had no effect. Importantly, no Ca2+ 
influx was induced by the addition of JJN3 cells (Figure 5D, iv) or pH 6.5 medium (Figure 
5F) when 1°N cells were pre-treated with APETx2 for 2h.
Thus, the acidic extracellular microenvironment of JJN3 cells promotes neurite outgrowth 
and excites 1°N SNs via ASIC3 activation.
Role of ASIC3 in MMBP
We then determined the role of ASIC3 in MMBP by testing APETx2 in vivo. JJN3-bearing 
and sham mice were treated with a single intraplantar injection of APETx2 at day 25 (arrow 
in Figure 6A) and evaluated for changes in MMBP. APETx2 reduced mechanical allodynia 
as early as 1h after injection, which lasted until 12h and disappeared after 24h (Figure 6B, 
open square). As shown in Figure 2G, Baf A1 exhibited its analgesic effects 12h after 
injection until 24h (Figure 6B, open triangle) following a single intraperitoneal injection 
(arrow in Figure 6A).
Further, pERK1/2 and pCREB expression in DRG was decreased in APETx2- and Baf A1-
treated JJN3-injected mice compared to vehicle-treated JJN3-injected mice at 6h after 
APETx2 injection (Figure 6C).
Thus, inhibition of ASIC3 or V-ATPase by APETx2 or Baf A1 administered in an “as-
needed manner” alleviates MMBP, respectively. These results indicate that ASIC3 plays an 
important role in MMBP induced by acidic bone microenvironment.
The selective TRPV1 antagonist, SB366791, also alleviated mechanical allodynia and 
decreased pERK1/2 and pCREB in DRG in JJN3-injected mice following a single 
intraplantar injection (Supplemental Figure 2C and 2D).
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Effects of inhibition of both V-ATPase and ASIC3 on SNs on MMBP
The analgesic effects of APETx2 were observed 1h after injection and lost after 18h (Figure 
6B, open square), whereas Baf A1 exhibited its analgesic effects 12h after injection until 24h 
(Figure 6B, open triangle). We therefore examined if treatment of JJN3-injected mice with a 
combination of APETx2 and Baf A1 produces rapid and sustained analgesic effects on 
MMBP. As expected, combined treatment with a single intraplantar injection of APETx2 
and a single intraperitoneal injection of Baf A1 decreased mechanical allodynia (Figure 6B, 
closed square) as early as 1h after injection to a greater extent and for a longer period than 
did each agent alone.
Expression of pERK1/2 and pCREB in DRG in JJN3-injected mice was also more 
profoundly down-regulated by the combined treatment than each agent alone (Figure 6C).
Contributions of OCLs to MMBP
OCLs express a3V-ATPase on their plasma membrane in the ruffled border (15,47) through 
which H+ are secreted during bone resorption, creating an acidic extracellular 
microenvironment (15–17). Histological examination of bone of JJN3-injected mice showed 
that the pits formed by TRAP+ OCLs on endosteal bone surfaces (Figure 7A, top) were 
acidic (Figure 7A, bottom, arrowheads), and that CGRP+ SNs innervated in close proximity 
to TRAP+ OCLs (Figure 7B). These findings suggest that the OCL-generated acidic 
microenvironments can directly activate pH-sensitive SNs in bone and elicit MMBP. To 
determine the role of OCLs in SN activation and MMBP, we tested the potent inhibitor of 
OCLs, zoledronic acid (ZOL), which reduces MMBP in patients (2). JJN3-injected mice 
(Figure 7C, closed circle) were treated with ZOL at day 10, 14 and 18 (arrows in 7C) using 
an established protocol (48). ZOL significantly reduced mechanical allodynia (Figure 7C, 
closed triangle). Of note, however, the analgesic effects of ZOL were lost at day 35. These 
results are consistent with the clinical observations that ZOL does not prevent the 
progression of bone pain in MM patients at advanced stages (2,3,22), and suggest that 
suppression of OCL bone resorption no longer ameliorates MMBP and that MM cells 
predominantly contribute to MMBP at advanced stages.
Effects of inhibition of both OCLs and V-ATPase on MMBP
We therefore examined if inhibition of H+ release via V-ATPase from JJN3 cells by Baf A1 
alleviates MMBP that became refractory to analgesic effects of ZOL. As already shown in 
Figure 2G and Figure 6B, a single intraperitoneal injection of Baf A1 to untreated JJN3-
bearing mice reduced MMBP (Figure 7D, closed diamond). Of note, a single intraperitoneal 
injection of Baf A1 to ZOL-treated JJN3-bearing mice that lost responsiveness to analgesic 
effects of ZOL at day 35 (arrowhead in 7C) decreased mechanical allodynia (Figure 7D, 
closed square) as early as 1h until 24h. Further, the combination of Baf A1 and ZOL 
decreased pERK1/2 and pCREB expression in DRG more profoundly than did ZOL or Baf 
A1 alone (Figure 7E). These results indicate that V-ATPase on MM cells as well as OCLs 
contribute to SN excitation and MMBP at advanced stages of MM.
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Discussion
We investigated the contributions of the acidic bone microenvironment associated with MM 
colonization in bone to MMBP. We showed that bone-colonizing JJN3 cells release H+ via 
V-ATPase, creating an acidic bone microenvironment. This pathological acidic 
microenvironment then stimulates the sprouting of CGRP+ SNs innervating bone and 
activates the acid-sensing nociceptors, ASIC3, on the CGRP+ SNs, which in turn excites the 
SNs to evoke MMBP. Blocking H+ release and development of the acidic bone 
microenvironment by the selective V-ATPase inhibitor, Baf A1, decreased the sprouting of 
CGRP+ SNs in bone, inhibited the excitation of the SNs and reduced MMBP in JJN3-
injected mice. Inhibiting H+-induced activation of ASIC3 by the specific ASIC3 antagonist, 
APETx2, inhibited SN excitation and alleviated MMBP. Further, a combination of a single 
injection of Baf A1 and APETx2 showed greater and longer analgesic effects on MMBP 
than each agent alone. Taken together, these results indicate that secretion of H+ via V-
ATPase on MM cells and subsequent activation of SNs by H+ via ASCI3 are key steps 
responsible for inducing MMBP and that these steps could be mechanism-based targets for 
treatment of MMBP in patients.
Our results for the first time show that not only OCLs but also MM cells directly contribute 
to SN activation to evoke MMBP through releasing H+ via V-ATPase. The result in part 
explains the observations that OCL-specific inhibitors alone reduce MMBP at early to 
advanced stages, however, fail to prevent the progression of MMBP at advanced to terminal 
stages of the disease (2,20). Consistent with these observations, ZOL reduced MMBP at 
early stages but lost its analgesic effects at terminal stages in our animal model. Of 
importance, amelioration of MMBP was restored by additional administration of a single 
injection of Baf A1 to ZOL-treated mice, demonstrating that blockade of H+ release from 
MM cells via suppression of V-ATPase mitigates MMBP refractory to the analgesic action 
of ZOL. These results suggest that administration of V-ATPase inhibitor combined with 
OCL inhibitor may be an effective approach for management of MMBP in patients with 
advanced MM.
ZOL was shown to decrease tumor burden in preclinical models of MM (48). Thus, 
alleviation of MMBP by ZOL in JJN3-injected mice could be secondary to decreased MM 
tumor burden rather than inhibition of OCL bone resorption. However, clinical observations 
that ZOL fails to prevent the progression of MMBP at advanced stages of the disease (2,20) 
together with our results suggest that the analgesic effects of ZOL are unlikely accounted by 
inhibition of MM growth.
Expression of the acid-sensing nociceptor TRPV1 was also increased on CGRP+ SNs in 
JJN3-injected mice. Previous studies reported that TRPV1 antagonists or disruption of the 
TRPV1 gene attenuated cancer-induced bone pain (28,29). We also showed that a single 
intraplantar injection of the selective TRPV1 antagonist, SB366791, significantly decreased 
SN excitation and MMBP in JJN3-injected mice. TRPV1 on SNs is activated at pH < 6.0 
(27). The pHe of the acidic microenvironment created by JJN3 cells and bone-resorbing 
OCLs is 6.5–6.9 (Figure 3) and 4.5–6.0 (15–17), respectively. These results suggest that the 
pHe of specific areas in JJN3-colonized bone may be < 6.0, a pH at which TRPV1 is 
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activated. We propose that the pHe of MM-colonized bone varies spatially and temporally, 
and induces activation of either ASIC3, TRPV1 or both on pH-sensitive SNs to induce 
MMBP, depending on the status of MM progression and OCL bone resorption.
Although our results demonstrate significant contribution of bone-resorbing OCL to MMBP 
in JJN3-injected mice, OCL bone resorption that occurs under physiological conditions 
rarely induces bone pain. As an explanation for this, recent studies reported that TRPV1 and 
ASIC3 dramatically decrease their threshold for sensing noxious stimuli in the presence of 
tissue damage and inflammation (18). Thus, it is speculated that SNs are not sensitive 
enough to be excited to evoke bone pain in response to acidic microenvironments created by 
physiological OCL bone resorption. Further, episodic musculoskeletal pain termed “growing 
pain” that often occurs in children in early childhood (49) suggests that bone turnover rate 
may be critical.
Solid tumors express various plasma membrane pH-regulators, including V-ATPase, 
monocarboxylate transporter 1/4, and carbonic anhydrases (24) through which H+ are 
extruded to avoid intracellular acidification due to elevated aerobic glycolysis (Warburg 
effect) (50), and acidify the extracellular microenvironment. Among these pH-regulators, 
a3V-ATPase has been implicated in solid cancer invasiveness and metastasis (25,44). We 
previously reported that suppression of a3V-ATPase in highly-metastatic B16-F10 
melanoma decreases bone metastasis (51). In contrast, if MM cells express V-ATPase was 
unknown. Here we show that JJN3 cells express plasma membrane a3V-ATPase that 
acidifies extracellular environments by releasing H+ and directly contributes to SN activation 
to induce MMBP. However, whether a3V-ATPase expression is associated with MM 
progression as is the case of solid tumors is unknown. Our results showed that a single 
injection of Baf A1 had no effects on JJN3 progression in bone and that Baf A1 did not 
inhibit JJN3 proliferation in culture, although long-term effects of Baf A1 on MM 
progression were not examined in this study. Interestingly, however, CD138+ primary cells 
derived from bone marrow of MM patients expressed a3V-ATPase, while little expression of 
a3V-ATPase was seen in CD138− cells. Further studies are needed to determine the 
relationship between a3V-ATPase expression and MM progression.
In conclusion, this study shows that the creation of acidic extracellular bone 
microenvironments by OCLs and MM cells via H+ secretion through plasma membrane V-
ATPase and responses of SNs innervating bone to the acidic microenvironment via ASIC3 
are critical contributors to the pathophysiology of MMBP. Targeting these pathways may 
provide mechanism-based effective therapies for control of MMBP, which is currently 
under-treated.
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Figure 1. Development of osteolytic lesions in JJN3-injected mice
A. Radiographs of osteolytic lesions (arrowheads).
B. 3D µ-CT images.
C. JJN3 cells in bone marrow with OCL bone resorption (arrowheads, HE, x400).
D. TRAP staining of bone (x40).
E. Number of TRAP+ OCL in bone. ** p<0.01 vs sham mice.
F. Serum CTx levels in mice. * p<0.05 vs sham mice.
G. Production of osteoclastogenic cytokines in JJN3 and MDA-MB-231 cells
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Figure 2. Bone pain and SN activation in JJN3-injected mice
A. Mechanical allodynia. * p<0.05, ** p<0.01 vs sham mice (mean ± SE, n=16). Arrow 
indicates a single intraperitoneal injection of Baf A1 (25µg/kg) or vehicle (0.1% DMSO in 
PBS).
B. Thermal hyperalgesia. * p<0.05 vs sham mice (mean ± SE, n=16). Arrow indicates a 
single intraperitoneal injection of Baf A1 (25µg/kg) or vehicle (0.1% DMSO in PBS).
C. Sprouting of CGRP+ SNs in tibiae.
D. Quantitative data of C. * p<0.05 vs sham mice (mean ± SE, n=16).
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E. Acidification of bone marrow shown by acridine orange accumulation.
F. Time-course of inhibition of mechanical allodynia, following a single intraperitoneal 
injection of Baf A1 (25µg/kg) or vehicle (0.1% DMSO in PBS) (arrow in A and B). * 
p<0.05 vs vehicle-treated JJN3-injected mice (mean ± SE, n=8).
G. Thermal hyperalgesia, following a single intraperitoneal injection of Baf A1 (25µg/kg) or 
vehicle (0.1% DMSO in PBS) (arrow in A and B). * p<0.05 vs vehicle-treated JJN3-injected 
mice (mean ± SE, n=8).
H. Excitation of sensory nerves determined by pERK1/2 and pCREB expression in DRG in 
sham and JJN3-injected mice.
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Figure 3. Expression of plasma membrane a3V-ATPase
A. a3V-ATPase expression in human MM cell lines (MM.1S, H929, U266 and JJN3), 
MC3T3-E1 mouse osteoblastic cells, MLO-A5 and MLO-Y4 mouse osteocytic cells, and 
MDA-MB-231 human breast cancer cells.
B. a3V-ATPase expression in primary CD138+ and CD138− cells derived from three MM 
patients.
C. Immunocytochemsitry of a3V-ATPase expression in JJN3 and MDA-MB-231 cells.
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D. pHe in cultures of human MM cell lines, CD138+ and CD138− cells, and MC3T3-E1, 
MLO-A5, MLO-Y4, and MDA-MB-231 cells. * p<0.05, ** p<0.01 vs control (mean ± SE, 
n=6).
E. Inhibition of acidification of pHe by Baf A1 (50ng/ml, 48h). * p<0.01 vs Baf A1-treated 
JJN3 cells (mean ±SE, n=6).
F. Effects of Baf A1 (50ng/ml, 48h) on cell proliferation (mean ± SE, n=6).
G. pHe in cultures of JJN3/sh a3V-ATPase or /sh control cells. * p<0.01 vs control. ** 
p<0.05 vs JJN3/sh control cells (mean ± SE, n=6).
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Figure 4. Sprouting and neurite outgrowth of SNs
A. Inhibition of mechanical allodynia by Baf A1 in JJN3-injected mice. Arrows: Baf A1 or 
vehicle injection. * p<0.05, ** p<0.01 vs sham mice. # p<0.05 vs vehicle-treated JJN3-
injected mice (mean ± SE, n=8).
B. Sprouting of CGRP+ SNs in tibiae. Left: CD138 (green); Center: CGRP (red); Right: 
merged image. Tibiae injected with, (top); PBS (sham), (middle); JJN3 cells and treated with 
vehicle, and (bottom); JJN3 cells and treated with Baf A1. Sections were incubated with 
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rabbit anti-CD138 (1:100) and goat anti-CGRP (1:200), then with donkey anti-rabbit IgG 
(1:100) and anti-goat IgG (1:100), respectively.
C. Quantitative analysis of B. * p<0.01 vs sham. ** p<0.01 vs vehicle-treated JJN3-injected 
tibiae (mean ± SE, n=6).
D. Neurite outgrowth from 1°N cells in co-culture with JJN3 cells. Co-cultures were treated 
with Baf A1 (50ng/ml) or vehicle (0.1% DMSO in PBS) for 5 days, labeled with calcein 
AM and quantitated.
E. Quantitative data of D. * p<0.01 vs 1°N cells alone. ** p<0.01 vs vehicle-treated co-
cultures (mean ± SE, n=6).
F. Neurite outgrowth of 1°N cells. * p<0.05 vs pH 7.4 (mean ± SE, n=6).
Hiasa et al. Page 21
Cancer Res. Author manuscript; available in PMC 2017 September 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. Role of ASIC3 in sprouting and excitation of SNs
A. Expression of ASIC3 (left, green) on CGRP+ SNs (center, red) in DRG from JJN3-
injected (top) and sham mice (bottom). Sections were incubated with a goat anti-CGRP 
(1:200) and rabbit anti-ASIC3 (1:300), then a donkey anti-goat IgG (1:100) and anti-rabbit 
IgG (1:100), respectively.
B. ASIC3 expression in DRGs isolated from JJN3-injected and sham mice.
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C. Neurite outgrowth from 1°N cells in co-cultures with JJN3 cells. Co-cultures were treated 
with Baf A1 (50ng/ml), APETx2 (0.5µM) or vehicle (0.1% DMSO in PBS) for 5 days. * 
p<0.05 vs 1°N cells alone. ** p<0.05 vs vehicle-treated co-cultures (mean ± SE, n=6).
D. Intracellular Ca2+ mobilization in co-cultures. 1°N cells were loaded with fura 2AM 
(3µM), treated with APETx2 (0.5µM) (ii and iv) or vehicle (0.1% DMSO in PBS) (i and iii) 
for 2h, then received JJN3 cells (3 × 105/300µl) (iii and iv) (arrows) or culture medium (i 
and ii), incubated and Ca2+ influx determined.
E. Ca2+ influx in 1°N cells. 1°N cells were pre-treated with APETx2 (0.5µM) for 2h, treated 
with PBS or HCl (arrows) and Ca2+ influx determined.
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Figure 6. Contribution of a3V-ATPase and ASIC3 to MMBP and SN excitation
A. Mechanical allodynia. Arrow: a single injection of either vehicle, APETx2 (intraplantar), 
Baf A1 (intraperitoneal), or APETx2 combined with Baf A1. * p<0.05, ** p<0.01 vs sham 
(mean ± SE, n=8).
B. Time-course of inhibition of mechanical allodynia following treatment with either vehicle 
(0.1% DMSO in PBS), APETx2 (20µM), Baf A1 (25µg/kg) or APETx2 plus Baf A1 (arrow 
in A) in sham and JJN3-injected mice. * p<0.05 vs JJN3-injected mice treated with 
vehicle. # p<0.05 vs JJN3-injected mice treated with APETx2 or Baf A1 (mean ± SE, n=8).
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C. Expression of pERK1/2 and pCREB in DRGs in mice shown in B at 12h.
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Figure 7. Contribution of OCL to MMBP and SN activation
A. Acidification of resorption lacunae formed on endosteal bone surfaces by TRAP+ OCLs. 
Top: TRAP+ OCLs (arrowheads) on endosteal bone surface. Bottom: Fluorescence of 
acridine orange accumulation in pits formed under OCLs (green). (x200)
B. Innervation of CGRP+ SNs (arrowheads) in the close proximity of TRAP+ OCLs 
(arrows). Sections were incubated with a goat anti-CGRP (1:200), followed by HRP-
conjugated donkey anti-goat IgG (1:100). Brown: CGRP+ SNs, Red: TRAP+ OCLs. (x400)
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C. Inhibition of mechanical allodynia by ZOL. Mice intratibially injected with JJN3 cells 
( , ) or PBS (sham) ( , ) were given vehicle (PBS) ( , ) or ZOL (120µg/kg) ( ,
) at day 10, 14 and 18 after JJN3 cell injection (arrows). At day 35, mice were given a 
single intraperitoneal injection of Baf A1 (arrow head). * p<0.05 vs vehicle-treated, JJN3-
injected mice (mean ± SE, n=8).
D. Effects of a single intraperitoneal injection of Baf A1 at day 35 (arrowhead in Figure 7C) 
on MMBP that became unresponsive to ZOL. At day 35, vehicle-treated JJN3-injected mice 
were given a single intraperitoneal injection of vehicle ( ) or Baf A1 ( ), and ZOL-treated 
JJN3-injected mice received a single intraperitoneal injection of vehicle ( ) or Baf A1 
(25µg/kg) ( ). * p<0.05 vs ZOL-treated JJN3-injected mice. # p<0.05 vs Baf A1-treated 
JJN3-injected mice (mean ± SE, n=8).
E. Expression of pERK1/2 and pCREB in DRG SNs in mice shown in D at 12h.
Hiasa et al. Page 27
Cancer Res. Author manuscript; available in PMC 2017 September 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
